What is Daurismo, and what AML setting is it for?
Daurismo is the brand name for gilteritinib. It is used in acute myeloid leukemia (AML) when the leukemia has a FLT3 mutation. Gilteritinib is intended for patients with relapsed or refractory AML (disease that returns after treatment or does not respond). [1]
How does Daurismo work against AML?
Daurismo targets FLT3 (fms-like tyrosine kinase 3). In AML with FLT3 mutations, FLT3 signaling helps drive leukemia cell growth and survival. By inhibiting FLT3, Daurismo can slow or stop that growth signal in FLT3-mutated AML. [1]
What happens to patients taking it (typical clinical goals)?
For relapsed/refractory FLT3-mutated AML, the treatment goal with Daurismo is to achieve a disease response (such as tumor/leukemia reduction) and improve outcomes compared with other available options for patients with this specific mutation profile. [1]
Who should be tested for before starting Daurismo?
Because Daurismo is aimed at FLT3-driven disease, patients with AML are generally evaluated for FLT3 mutations to confirm eligibility before using gilteritinib. [1]
Is it used with other AML therapies, or alone?
The provided information here focuses on Daurismo as an AML therapy in FLT3-mutated relapsed/refractory disease. Specific combination regimens depend on the clinical protocol and the patient’s situation. [1]
If you share the context you mean (for example, “newly diagnosed FLT3-mutant AML” versus “relapsed FLT3-mutant AML,” or whether you mean a particular line of therapy), I can narrow the explanation to that exact AML setting.
Sources
[1] https://www.drugpatentwatch.com/